CEO’s 147% Share Surge Signals Confidence in Longeveron’s Future
CEO buy‑back at Longeveron: 200k Class A shares purchased, 105k sold—boosting his stake by 147 % amid rising social‑media buzz and $16 m private placement, but clinical milestones remain key to long‑term value.
4 minutes to read